Psyched Wellness (CSE: PSYC) this morning issued a brief press release related to the ongoing pre-clinical trial of its muscimol extract, referred to as AME-1. The firm has received the results from its maximum tolerated dosage study, which was conducted through that of KGK Science.
The study is the first set of toxicology assessments being conducted on the Amanita Muscaria extract. The study for maximum tolerated dosage was required as part of the pre-clinical process, which will now see the company conduct studies focused on the oral toxicity of the product.
Two studies are to be conducted for the next phase of the development, with the firm to conduct both a 14 day and a 90 day oral toxicity study. Once completed, the data will be used to determine effective and safe dosages for human consumption of the extract.
“I am pleased to share the positive results from the individual studies that our CRO is conducting in the pre clinical study on our behalf for AME 1. Today’s results pushes us one step closer to our goal of applying to the FDA for a New Dietary Ingredient and to Health Canada for a Natural Health Product Number.”Jeff Stevens, CEO of Psyched Wellness
Psyched Wellness last traded at $0.50 on the CSE.
FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.